

# **Cardiac MRI: Cardiomyopathy**

**Laura E. Heyneman, MD**

**I do not have any relevant financial  
relationships with any commercial  
interests**

# **Cardiac MRI: Cardiomyopathy**

**Laura E. Heyneman, MD**

**Duke University Medical Center**

**heyne001@mc.duke.edu**

**www.radiologytalks.com**

# Outline

**Delayed enhancement**


- **patterns**

**Specific myopathies:**


- **dilated CM**
- **sarcoid**
- **hypertrophic**

# Cine Imaging

Breath held SSFP; real-time  
Wall motion, valves



short axis



2 chamber




4 chamber

# Delayed Enhancement

IR gradient echo

spoiled gradient echo, SSFP



short axis


3 chamber

4 chamber

# Delayed Enhancement

IR gradient echo

5-15 minutes after IV contrast




short axis

2 chamber

4 chamber

# Delayed Enhancement

Normal myocardium nulled




short axis

3 chamber

4 chamber


# Delayed Enhancement

Delayed enhancement =  
abnormal




# Delayed Enhancement

Delayed enhancement =  
abnormal





**Infarct**



**Myocarditis**

# Delayed Enhancement


Is enhancement in an  
ischemic pattern?



*Cardiol Clin* 2007; 25: 71-95

*RadioGraphics* 2006; 26: 795-810

# CAD Enhancement




**Subendocardial**



**Transmural**

# CAD Enhancement




**subendocardial**



**transmural**

# CAD Enhancement



**subendocardial**





**transmural**

# **Enhancement: Non-CAD Patterns**

- **Mid-myocardial**
- **Epicardial**
- **RV insertion**
- **Diffuse subendocardial**

# Non-CAD Pattern: Midmyocardial



*AJR* 2005; 184: 1420-1426

*Int J Cardiovasc Imaging* 2008;24:597-608

# Non-CAD Pattern: Midmyocardial


Myocarditis

Hypertrophic


Dilated CM

Sarcoidosis


Chagas disease



# Non-CAD Pattern: Midmyocardial




**myocarditis**





# Non-CAD Pattern: Midmyocardial



**hypertrophic CM**



# Non-CAD Pattern: Epicardial




# Non-CAD Pattern: Epicardial


**Myocarditis**

**Sarcoidosis**


**Chagas disease**




# Non-CAD Pattern: Epicardial



**Sarcoid**



# Non-CAD Pattern: RV insertion site




*AJR* 2005; 184: 1420-1426


*Int J Cardiovasc Imaging* 2008;24:597-608

# Non-CAD Pattern: RV insertion site

**RV overload**



# Non-CAD Pattern: RV insertion site




**Pulmonary valve stenosis**

# Non-CAD Pattern: RV insertion site




**Pulmonary valve stenosis**

# Non-CAD Pattern: RV insertion site



**Pulmonary valve stenosis**

# Non-CAD Pattern: diffuse subendocardial



*AJR* 2005; 184: 1420-1426

*Int J Cardiovasc Imaging* 2008;24:597-608


# **Non-CAD Pattern: diffuse subendocardial**

**Amyloidosis**

**System sclerosis**

**Cardiac trxplt**


**(Uremic CM)**




# Non-CAD Pattern: diffuse subendocardial




**Amyloid**



# Non-CAD Pattern: diffuse subendocardial





**Amyloid**




# Myocardial Diseases

**Dilated  
cardiomyopathy:  
ischemic or not?**

**56 yo CHF; EtOH;  
known CAD (LCx > 50%)**




# Ischemic



**RV spared**

**Focal thinning**


# Nonischemic



**Biventricular**


**Uniform wall**

# Ischemic




**Enhancement:  
subendocardial,  
transmural**

# Nonischemic




**Enhancement:  
none**

# Ischemic




**Enhancement:  
subendocardial,  
transmural**

# Nonischemic



**Enhancement:  
none**

# Ischemic



**Enhancement:  
subendocardial,  
transmural**

# Nonischemic




**Enhancement:  
none,  
nonischemic**

# Nonischemic Cardiomyopathy

No Enhancement

Alcoholic, Post-partum, Idiopathic





# Nonischemic Cardiomyopathy

40% idiopathic CM


nonischemic pattern: midwall




**56 yo CHF; EtOH;  
known CAD (LCx > 50%)**




**56 yo CHF; EtOH;  
known CAD (LCx > 50%)**




# Nonischemic Cardiomyopathy



# Alcoholic Cardiomyopathy



**Revascularization?  
probably not improve**



**Sudden cardiac  
death  
in young patient:  
? cause**

# **Sudden Cardiac Death in Young Patient**

- **Cardiac sarcoid**
- **Hypertrophic CM**
- **Arrhythmogenic RV dysplasia**
- **Anomalous coronary**

# **Sudden Cardiac Death in Young Patient**

- **Cardiac sarcoid**
- **Hypertrophic CM**
- **Arrhythmogenic RV dysplasia**
- **Anomalous coronary**

# **Sudden Cardiac Death in Young Patient**

- **Cardiac sarcoid**
- **Hypertrophic CM**
- **Arrhythmogenic RV dysplasia**
- **Anomalous coronary**


# Sudden Cardiac Death in Young Patient

- **Cardiac sarcoid**
- Hypertrophic CM
- Arrhythmogenic RV dysplasia
- Anomalous coronary

# Cardiac Sarcoidosis

- **Multi-organ system**
- **5% clinical cardiac dz**
- **Risk of arrhythmia, SCD**
- **Treatment: defibrillator**

# Sarcoidosis



Adapted from *Am J Med* 1977;63(1):86-108

**Granuloma  
deposition**

# **Japanese Ministry of Health Criteria A + at least 1 from B-D**



**Criteria A: Abnormal EKG or holter**

**Criteria B: Abnormal ECHO**

**Criteria C: Abnormal nuclear study  
(perfusion defect or abnormal 67-Ga citrate scan)**

**Criteria D: Abnormal cath  
(abnormal wall motion or EF)**



# MRI spatial resolution surpasses ECHO, nucs



*Cardiol Clin* 2007; 25: 71-95.


*AJR* 2005; 184: 1420-1426

# 45 yo, lung sarcoid, normal cath, +/- ECHO



**Aneurysm**

# Delayed Enhancement often nonischemic pattern





*Circulation* 2004;108:645 (suppl)

**Patel: 70 pts sarcoid  
24% + enhancement  
(2x Japanese criteria)**





*Circulation* 2006; 114 (suppl II): 408

# Patel: 70 pts sarcoid enhancement patterns transmural: nl coronaries





**Transmural**

**Patel: 70 pts sarcoid  
enhancement patterns  
82% focus nonischemic**



**Mid-myocardial**

**Patel: 70 pts sarcoid  
enhancement patterns  
82% focus nonischemic**



**Epicardial**

**Patel: 70 pts sarcoid**  
**DE: independent predictor**  
**of cardiac events**





*Circulation* 2006; 114 (suppl II): 408



*Cardiol Clin* 2007; 25: 71-95.



# Delayed Enhancement

? before function abnormal



# Delayed Enhancement

## target endomyocardial bx



# Sudden Death in Young Patient


- Cardiac sarcoid
- Hypertrophic CM
- Arrhythmogenic RV dysplasia
- Anomalous coronary

# **Hypertrophic Cardiomyopathy**

- **LV hypertrophy, no cause**
- **Genetic**
- **Sudden death:  
arrhythmia, LVOT obstruction**



# Hypertrophic Cardiomyopathy:

Wall thickness  $> 1\text{cm}$





*N Engl J Med* 2004; 350:1320-1327

# Hypertrophic Cardiomyopathy: Concentric hypertrophy





*N Engl J Med* 2004; 350:1320-1327

# Hypertrophic Cardiomyopathy: Asymmetric: apical





# Hypertrophic Cardiomyopathy: Asymmetric: septal



*N Engl J Med* 2004; 350:1320-1327



# Hypertrophic Cardiomyopathy:

Septal: ?LVOT obstruction





# Hypertrophic Cardiomyopathy:

Septal: ?LVOT obstruction





# Hypertrophic Cardiomyopathy:



Jet / turbulent flow in LVOT




# Characteristic SAM: Systolic Anterior Motion of anterior leaflet MV




# Hypertrophic Obstructive Cardiomyopathy (HOCM)




# Delayed enhancement: patchy, midmyocardial





# Delayed enhancement: jxn of septum, RV free wall



# Delayed enhancement: 81% HCM patients: + scar




# Delayed enhancement: + collagen; ? ischemia



*J Am Coll Cardiol* 1986; 8 (3):545-557.

*J Am Coll Cardiol* 2004; 43 (12):2260-4.


# Delayed enhancement: ? arrhythmogenic foci



# Delayed enhancement: ? ↑ scar: ↑ risk SCD ?




# Delayed enhancement: LVDT > 3 cm; ↑ risk SCD



*J Am Society Echocardiogr* 2006; 19(6): 788-795.


# Treatment for HOCM: EtOH ablation




**Pre ablation**

*J Am Coll Cardiol* 2004; 43(1):27-34.

# Treatment for HOCM: EtOH ablation





**Pre ablation**



**Post ablation**

# Treatment for HOCM: EtOH ablation





**LAD infarction post ablation**

**Laura E. Heyneman, MD**  
**heyne001@mc.duke.edu**  
**www.radiologytalks.com**



**Unknown case 1**

# 45 yo, arrhythmia




**Delayed  
enhancement**



# Lateral wall dyskinesia





# Transmural enhancement





# Epicardial enhancement



# Epicardial enhancement: nonischemic cardiomyopathy





# Nonischemic cardiomyopathy: ? sarcoid, ? myocarditis





# Chagas disease






**Unknown case 2**





**40 yo, dyspnea, anasarca**











# Bilateral reticulonodular; confluent opacity in RML


















**DE**




**DE**





# Abnormal lung signal



**DE**




**DE**





# LV + RV hypertrophy



**DE**




**DE**





# diffuse subendocardial DE



**DE**




**DE**



# RV enhancement



**DE**



**DE**

# **Amyloid**

**(pulmonary + cardiac)**

**Laura E. Heyneman, MD**  
**heyne001@mc.duke.edu**  
**www.radiologytalks.com**